DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm
The owner of DIAGOMICS has sold the company to ZytoMax GmbH.
Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.
Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.
Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.
Gwénola Tanneau
Founder and CEO, DIAGOMICS
Contáctese con el equipo de la transacción
Transacciones relacionadas
Den Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Conozca másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Conozca másMicrofinanciera Fundeser has been sold to Grupo Financiero Atlántida
Incofin has successfully exited its investment in Microfinanciera Fundeser in Nicaragua through two of its funds: Rural Impulse Fund II (RIF II) and agRIF. It has sold 100% of its stake in Microfinanciera Fundeser to Grupo Financiero Atlántida through its subsidiary, Inversiones Tres Lagos.
Conozca más